RGCC Oncotrace serves as a valuable follow-up tool, accurately evaluating the therapeutic response of cancer treatment. It furnishes essential data necessary for comprehending and anticipating the prognosis of cancer.
Oncotrace
Whole peripheral blood sample
15-25ml blood
All Types
21 days
RGCC Oncotrace guides disease progression and future prognosis. It also helps to identify a patient’s primary tumor in case of unknown primary origin. It precisely assesses the therapeutic response of cancer treatment and provides data that is pivotal for informed decision-making to enhance your overall health and well-being. The test assesses prognosis assessment and disease progression.
The blood sample is meticulously examined to pinpoint the presence and concentration of Circulating Tumor Cells (CTCs)
CTCs are characterized based on the expression of specific cell surface markers or antigens using immunological techniques that help identify and isolate Cancer Stem Cell (CSC) populations and phenotype markers
RGCC Oncotrace delivers three crucial pieces of information:
CTC count: Helps to determine the complexity of the disease, studies show a direct correlation between the CTC count and overall tumor burden. The CTC count helps clinicians assess the treatment responses.
Phenotype markers: Offers insights into the tissue of origin of the cells where multiple primary cancer tumors exist in the body. Knowing the primary origin can influence the choice of treatment modalities that optimize patient outcomes by targeting the disease’s biological characteristics and underlying mechanisms.
Stemness markers: Indicate that certain cancer cells possess characteristics similar to those of stem cells, including self-renewal, differentiation potential, and the ability to initiate and sustain tumor growth. Identifying stemness markers in cancer is important for understanding the biology of cancer stem cells (CSCs) and their role in tumor initiation, progression, metastasis, and treatment resistance.
The combination of multiple markers is often considered to create a comprehensive profile of the cancer biology and this test serves as an invaluable tool for interim cancer monitoring.
Oncotrace is a baseline test that provides data on the status of your cancer before starting the treatment. The test provides information on cancer progression and prognosis which is pivotal for informed decision making.
The test applies to all types of cancer and is not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
A simple non-invasive test to monitor cancer.
We suggest undergoing the RGCC Oncotrace test every three months during active cancer treatment to evaluate the efficacy of the ongoing treatment plan.
Every 3 months for 1 year after completing the treatment/surgery to monitor for early relapse/recurrence.
Once patients achieve full remission (when the CTC count is below 1 and all the CSC markers are negative), the test is recommended every six months.)
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Are you looking for precise insights into your therapeutic response? RGCC OncoTrace is an advanced tool to gain the clarity needed to make informed decisions and improve your treatment outcomes. Take charge of your cancer journey with confidence.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media
Dr. Vikas AgarwalSenior Surgical Oncologist, Kolkata